ArticleFrontiers in medicine2025

Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian cancer in randomized, double-blind, phase III controlled trials: protocol for a systematic review and network meta-analysis.

Xiaolian Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.